2021 ASCO Updates From LIMBER-313 on Myelofibrosis: Parsaclisib + Ruxolitinib for JAKi/PI3Ki Treatment-Naïve Patients
By
The University of Kansas Cancer Center
FEATURING
Abdulraheem Yacoub
By
The University of Kansas Cancer Center
FEATURING
Abdulraheem Yacoub
Login to view comments.
Click here to Login